RALEIGH, N.C., Jan. 5, 2010 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) announced today that Richard A. Franco, R.Ph., Chief Executive Officer and President, is scheduled to present at the Sidoti & Company 2010 Micro Cap Conference being held in New York City on January 11, 2010. DARA's presentation is scheduled for 10:30 a.m. EST at the Grand Hyatt New York, located at 109 East 42nd Street at Grand Central Terminal.
Investors will also be able to arrange one-on-one meetings with Richard Franco in advance. The exclusive event is available to on-site attendees only. For additional information or to schedule a one-on-one meeting with DARA at this event, please contact Kevin McGrath at kevin@cameronassoc.com/212 245 4577or Lynn Orenstein at lorenstein@sidoti.com/212 453 7031.
Richard Franco will also be presenting at the OneMedForum 2010 Emerging Company Finance Conference being held in San Francisco on January 12-14, 2010. DARA's presentation is scheduled for Wednesday, January 13 at 10:15am PST/1:15pm EST at the Sir Francis Drake Hotel, Union Square located at 450 Powell Street.
The OneMedForum provides an opportunity for the most promising emerging healthcare and life science companies to present and interact with a diverse group of global investors and partners. The 2010 event will feature Public and Private Company tracks and a session on Healthcare IT and the impact of reform and opportunities related to the stimulus package.
Conference participants may arrange one-on-one meetings with Richard Franco in advance through the OneMedForum website.
A copy of the management presentation will be posted on January 11, 2010, at www.darabiosciences.com in the Investor Relations section.
About DARA BioSciences, Inc.
DARA BioSciences, Inc. is a Raleigh, North Carolina based development-stage biopharmaceutical company that acquires promising therapeutic small molecules and develops them through proof of concept in humans for subsequent sale or out-licensing to larger pharmaceutical companies. Presently DARA has two drug candidates with cleared IND's (Investigational New Drug) Applications from the US FDA. One of these drug candidates, KRN5500, has successfully completed a Phase 2a clinical trial treating cancer patients for neuropathic pain. It has a portfolio of drug candidates for neuropathic pain, type 2 diabetes, and psoriasis. For more information please contact the Company at 919-872-5578 or visit our web site at http://www.darabio.com.